# iM Investment Partners

> iM Investment Partners is a VC fund backing Pharmaceutical and Biotechnology. See 13 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 13
- Last investment: Apr 2026
- Lead investor: 8%
- Last updated: Aug 2026
- Website: https://im-investment.com

iM Investment Partners is an investment firm. It is an affiliate of DGB Finance Group.

## Contacts

5 contacts available for iM Investment Partners. Shizune tracks 1 team members at iM Investment Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/im-investment-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Pharmaceutical | 5 | 38% |
| Biotechnology | 4 | 31% |
| Health Care | 3 | 23% |
| Biopharma | 2 | 15% |
| Manufacturing | 2 | 15% |

28 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 23% |
| Series A | 3 | 23% |
| Series B | 3 | 23% |
| Series C | 2 | 15% |
| Series D | 1 | 8% |

6 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Kwon Jun-hee | Founder & CEO | 0 | https://shizune.co/investors/profile/kwon-jun-hee |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Automata | Automata creates AI-powered tools like AI agents and smart integrations that simplify how teams plan, communicate, and work. The company solves business problems by enabling AI to build, manage, and evolve software workflows while humans guide the AI to deliver real value.Automata provides industry-tailored AI solutions | $7.1M | Series A | Apr 24, 2026 |  |
| IVWorks | IVWorks has been at the forefront of the compound semiconductor industry .We are clearly recognized as the high-tech innovator of advanced wide bandgap semiconductor epitaxial wafer products and wafer services to the semiconductor industry.IVWorks technology leadership and passion towards the innovation enable the company to provide a uniqueservice that is second to none.The epitaxial wafer products that we manufacture can be used by chip companies to produce the chips which enable a wide range of high-tech applications. The unique properties of these materials enable a diverse range of markets including wireless communications, advanced solar power, high efficiency LED lighting, efficient power switching and a range of consumer and industrial applications using advanced power devices.Beyond this, IVWorks is also working with leading R&D groups and on a number of major government funded programs to develop the next generation of technology which will combine the scale and maturity of the silicon industry with the advanced properties of compound semiconductors. | $3.9M | Venture - Series Unknown | Apr 02, 2026 |  |
| Anabatic Semiconductor | Anabatic Manufacturing of electronic components, computers, video, audio, and communication equipment | $10M | Series B | Mar 25, 2026 |  |
| Ticaros | Ticaros is a biotech company that develops immune anti-cancer drugs. | $14M | Series D | Mar 03, 2026 |  |
| Partridge Systems | Partridge Systems develops an automotive data platform that enables real-time data transfer, sharing, and structured data management. The platform offers end-to-end capabilities, including data collection, storage, and deployment pipelines for processing vehicle big data through web-based visualization tools. It allows users to access streamingdata without local downloads and supports seamless collaboration among engineers worldwide. | $4.3M | Series A | Nov 26, 2025 |  |
| MediMabBio | MediMabBio platform uses systems biology combined with sophisticated immunological solutions to identify significantly improving immuno-oncology drugs that can actively target a range of solid tumors. The antibody discovery I-O platform brings the advantages of rational drug design to large molecule therapeutic development. | $17.8M | Series B | Oct 24, 2025 |  |
| Lutem Bio | Lutem Bio is an online medicine firm that is intended for general health. The company provides medicine for memory, cognition, immunity, gut, joints, and bones, among others, enabling customers to get medicines recommended by a doctor. | $3M | Series A | Oct 17, 2025 |  |
| Yeoshin | Yeoshin is a skin treatment information platform. | $7.2M | Series C | Sep 08, 2025 |  |
| SCBIO | SCBIO is a pharmaceutical company that makes drugs with specialized technologies in immuno-oncology. The company discovers and develops novel therapeutics for future medicine. | $10M | Seed | Sep 01, 2025 |  |
| DOD | DOD is data-driven musical business platform. | $8.5M | Seed | Dec 06, 2024 |  |

10 of 13 investments shown.

## Co-investors
- [Enlight Ventures](https://shizune.co/investors/profile/enlight-ventures) — VC Fund, 3 deals together
- [Union Investment Partners](https://shizune.co/investors/profile/union-investment-partners) — VC Fund, 3 deals together
- [E&Venture Partners](https://shizune.co/investors/profile/e-venture-partners) — VC Fund, 2 deals together
- [IBK Capital](https://shizune.co/investors/profile/ibk-capital-951b) — VC Fund, 2 deals together
- [Industrial Bank of Korea](https://shizune.co/investors/profile/industrial-bank-of-korea) — VC Fund, 2 deals together
- [KB Investment](https://shizune.co/investors/profile/kbinvest) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Warner Music Group](https://shizune.co/investors/profile/warner-music-group) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Goodwater Capital](https://shizune.co/investors/profile/goodwater-capital) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [Music VC Funds in South Korea](https://shizune.co/investors/music-vc-funds-south-korea)

## FAQ

### What does iM Investment Partners invest in?

iM Investment Partners invests primarily in Pharmaceutical, Biotechnology and Health Care startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact iM Investment Partners?

Public channels for iM Investment Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at iM Investment Partners?

The team at iM Investment Partners includes Kwon Jun-hee (Founder & CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co